Leave Your Message
ADT1061-Avelumab Biosimilar– Anti-PD-L1 mAb – Research Grade

Hot

ADT1061-Avelumab Biosimilar– Anti-PD-L1 mAb – Research Grade

  • Catalog Number ADT1061
  • Host CHO Cells
  • Species Human
  • Target CD274/B7-H1/PDL1
  • Application Elisa, WB

CD274, Also known as PDL1, it is a ligand that binds to the common receptor PD1 on T cells and is used to block T cell activation. PD1 expression has been observed in various cancers, including melanoma and non-small cell lung cancer. The interaction between PD1 and PDL1 is considered a possible mechanism by which tumors evade immune responses. Many checkpoint blockade inhibitors have been developed, including pembrolizumab and nivolumab, which target the PD1/PDL1 interaction, allowing T cells to recognize tumor cells without being inactivated by the tumor.

Alpha Lifetech offers flexible ordering options for biosimilar antibody products, providing both small and large quantities to suit different needs.

Products Categories
Featured Products
recommended service
quick links
Contact Us

Product Background

B7-H1, referred to as Programmed cell death 1 ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) or B7-H1, is encoded by the CD274 gene. PD-L1 is a ligand for PD-1, that is, a protein that can bind to PD-1. It consists of 290 amino acid residues, including mainly the short cytoplasmic tail region, the transmembrane region, and the IgV and IgC-like extracellular domains. PD-L1 is expressed in both hematopoietic and nonhematopoietic cells and on the tumor surface. PD-L1 is also expressed on the surface of antigen-presenting cells (DC cells, macrophages, etc.), and the surface of vascular endothelial cells.

Product Specification

Catalog Number

ADT1061

Product Name

ADT1061-Avelumab Biosimilar– Anti-PD-L1 mAb – Research Grade

Alias

MSB-0010718C, MSB0010682

Isotype

IgG1 Lambda

Clonity

Monoclonal

Alternate Names

cd274 gene, pd-l1 gene, pd-l1 antibody, human pd-l1 antibody, mouse pd-l1, human cd274, recombinant cd274, Avelumab Biosimilar

Official Symbol

CD274/B7-H1/PDL1

Species

Human

Expression Host

CHO Cells

Reactivity

Human

Gene ID

29126

CAS Number

1537032-82-8

Chemical Formula

C6374H9898N1694O2010S44

Molecular Weight

35.5KDa

Product Description

Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma.

Mechanism of Action

PD-L1 may be expressed on tumor cells and tumor-infiltrating immune cells and can contribute to the Inhibitionition of the anti-tumor immune response in the tumor microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production. Avelumab binds PD-L1 through the FG loops and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1. This interaction releases the Inhibitionitory effects of PD-L1 on the immune response resulting in the restoration of immune responses, including anti-tumor immune responses. Avelumab has also been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. In syngeneic mouse tumor models, blocking PD-L1 activity resulted in decreased tumor growth.

Metabolism

Avelumab undergoes nonspecific proteolytic degradation.

Size

1mg,5mg

Research Area

Cancer

Application

Elisa, WB

Purity

>95% as determined by SDS-PAGE

Concentration

Batch dependent

Buffer

Supplied in PBS, PH7.5

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

Shipped on ice packs.

Note

This product is for research use only. 

Reference

1.Tian X, et al. Biomolecules, 2023 Jun 15. PMID 37371571
2.Kubes V, et al. In Vivo, 2023 Jul-Aug. PMID 37369476
3.Adiputra PAT, et al. Asian Pac J Cancer Prev, 2023 May 1. PMID 37247264

 

FAQ

Leave Your Message